Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk for patients with indeterminate biopsies. The company develops and commercializes genomic tests that personalize medicine to improve patient diagnosis and management. Its current focus is on molecular diagnostic tests for thyroid cancer, specifically ThyGeNEXT® and ThyraMIR® v2, following the discontinuation of the PancraGEN® test for pancreatic cyst risk assessment after CMS ceased reimbursement coverage in May 2025. Interpace Biosciences operates a CLIA-certified and CAP-accredited laboratory in Pittsburgh, Pennsylvania, where it performs testing on fine-needle aspiration biopsies from thyroid nodules to inform surgery or surveillance decisions. The company’s tests enable healthcare providers to stratify cancer risk, helping avoid unnecessary surgical procedures while identifying patients who may benefit from intervention.
Interpace Biosciences generates revenue primarily through reimbursement for its molecular diagnostic tests from Medicare, Medicare Advantage, Medicaid, and commercial payers such as Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare, as well as direct client billings to hospitals, clinics, and laboratories. The company’s largest customer in 2025 for ThyGeNEXT® and ThyraMIR® v2 was Laboratory Corporation of America (LabCorp). Revenue is derived from test volumes tied to reimbursement rates and coverage policies, with ongoing efforts to secure broader insurance coverage and maintain existing reimbursement levels. Interpace Biosciences also pursues growth through automation, operating efficiencies, and expanding its commercial sales team to increase awareness and adoption of its endocrine cancer assays. The company invests in research and development to enhance its existing tests and explore new diagnostic solutions, while leveraging its bioinformatics data to improve assay performance and scientific understanding of cancer progression.
Interpace Biosciences operates through the following segments:
- Clinical services: This segment commercializes clinically useful molecular diagnostic tests and molecular pathology services focused on risk-stratification of cancer to personalize medicine and improve patient diagnosis and management. The segment offers esoteric diagnostic tests principally focused on thyroid nodules, providing pathological, mutational, and epigenetic analysis of fine-needle aspiration biopsies. Key products include ThyGeNEXT®, an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules, and ThyraMIR® v2, a microRNA gene expression classifier used in combination with ThyGeNEXT® to refine malignancy risk. ThyGeNEXT® evaluates common mutations associated with thyroid cancer and provides clinical utility aligned with FDA-approved therapies for markers such as RET and NTRK. ThyraMIR® v2 measures expression of eleven distinct microRNAs through algorithmic and pairwise analysis to further refine risk assessment, especially when weaker drivers like RAS-like mutations are present. The combined ThyGeNEXT® and ThyraMIR® v2 platform delivers high-performance metrics and narrow malignancy risk ranges to guide patient management decisions. The company estimates the total addressable market for its endocrine (thyroid) cancer assays is approximately $300 million annually based on patient population size, indeterminate biopsy volume, and reimbursement rates.
Interpace Biosciences operates in the competitive esoteric molecular diagnostics market, which is projected to grow from $29.6 billion in 2025 to $75.9 billion by 2034 at a CAGR of 11.12%. The company faces competition from larger entities such as Veracyte, Inc. (Afirma test), Quest Diagnostics Incorporated (which distributes Afirma and offers similar tests), and Sonic Healthcare USA, Inc. (ThyroSeq® test using next-generation sequencing). Despite having fewer resources than some competitors, Interpace Biosciences differentiates itself through scientific expertise, test performance, and a focus on endocrine cancer diagnostics. Its competitive advantages include proprietary technology, CLIA and CAP accreditation, and a growing intellectual property portfolio with ten issued U. S. patents and four foreign patents as of December 31, 2025. The company also benefits from its ability to provide actionable diagnostic information that may reduce unnecessary surgeries and lower healthcare costs, a value proposition supported by clinical evidence and payer engagements.
Interpace Biosciences serves physicians, hospitals, cancer centers, clinics, commercial laboratories, and pathology groups. Its customers rely on the company’s clinical services to guide patient management decisions by providing diagnostic and prognostic information on indeterminate specimens. The company also provides guidance on genetic marker-related pharmaceutical treatment options when available. Laboratory Corporation of America (LabCorp) is identified as the largest customer for ThyGeNEXT® and ThyraMIR® v2 in 2025. The company’s revenue channels include reimbursement from federal and state healthcare programs, private insurers, and direct billing to institutional clients such as hospitals and clinics.